David E. Nichols | Academic Influence

Why Is David E. Nichols Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Earl Nichols is an American pharmacologist and medicinal chemist. Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the method that is used to make the optical isomers of hallucinogenic amphetamines. His contributions include the synthesis and reporting of escaline, LSZ, 6-APB, 2C-I-NBOMe and other NBOMe variants , and several others, as well as the coining of the term "entactogen".

(See a Problem?)

David E. Nichols's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Brine shrimp: a convenient general bioassay for active plant constituents. (1982) (4399)
Functional Selectivity and Classical Concepts of Quantitative Pharmacology (2007) (1069)
Serotonin receptors. (2008) (677)
Psychedelics (2016) (601)
Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. (1986) (487)
Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. (1986) (289)
Crystal Structure of an LSD-Bound Human Serotonin Receptor (2017) (247)
Effects of Schedule I drug laws on neuroscience research and treatment innovation (2013) (236)
Serotonergic basis of antipsychotic drug effects in schizophrenia (1998) (210)
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. (1998) (196)
Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. (1987) (191)
Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists (2006) (185)
Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. (1982) (184)
Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. (1991) (176)
Brine shrimp: a convenient general bioassay for active plant constituents. (1982) (176)
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. (1990) (160)
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. (1986) (158)
The G Protein–Biased κ-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo (2015) (152)
Modification and evaluation of the potato disc assay and antitumor screening of euphorbiaceae seeds. (1982) (147)
Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves (2003) (144)
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor (2020) (143)
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. (1991) (141)
WAY-100635 is a potent dopamine D4 receptor agonist (2006) (139)
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. (2002) (132)
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. (1995) (126)
D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. (1991) (118)
[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. (1991) (113)
A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases (2003) (111)
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. (1992) (109)
Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. (1989) (107)
Asymmetric synthesis of psychotomimetic phenylisopropylamines. (1973) (106)
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. (1996) (105)
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis (2005) (104)
Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. (2001) (97)
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. (2000) (93)
Psychedelic Drugs in Biomedicine. (2017) (92)
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. (2004) (91)
Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. (1998) (87)
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia (2007) (87)
Structure‐Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs? a (1990) (86)
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. (2006) (85)
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research (2019) (84)
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia (2007) (84)
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. (2002) (84)
Absolute configuration and psychotomimetic activity. (1978) (83)
Reinforcing effects of certain serotonin-releasing amphetamine derivatives (1996) (82)
Drug discrimination studies with MDMA and amphetamine (2004) (81)
Nickel boride/hydrazine hydrate reduction of aromatic and aliphatic nitro compounds. Synthesis of 4-(benzyloxy)indole and .alpha.-alkyltryptamines (1986) (80)
Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. (1999) (78)
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). (1990) (75)
Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors (1994) (75)
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. (2005) (74)
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. (1997) (74)
p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. (1992) (69)
Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists (1995) (68)
D1 dopamine receptors. (2001) (67)
Differential Activation of Adenylate Cyclase and Receptor Internalization by Novel Dopamine D1 Receptor Agonists (2005) (67)
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. (1998) (66)
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. (1993) (65)
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. (1991) (65)
Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand (1989) (63)
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. (1996) (63)
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). (2002) (62)
Parkinson's disease and D1 dopamine receptors. (2001) (59)
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. (2008) (59)
Serotonin 5‐HT2A receptor activation induces 2‐arachidonoylglycerol release through a phospholipase c‐dependent mechanism (2006) (59)
Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. (1993) (58)
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors (1995) (58)
8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A Potent Full Dopamine D1 Agonist Containing a Rigid β-Phenyldopamine Pharmacophore (1996) (57)
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. (1994) (57)
Psychostimulant-like effects of p-fluoroamphetamine in the rat. (1995) (56)
N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues (2014) (56)
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. (1994) (55)
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. (1987) (54)
Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action (2007) (54)
(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. (1990) (54)
Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. (1991) (54)
An animal model of schizophrenia based on chronic LSD administration: Old idea, new results (2011) (53)
[125I]-2-(2,5-Dimethoxy-4-Iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex (1990) (51)
Chemistry and Structure-Activity Relationships of Psychedelics. (2018) (51)
Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor (2007) (51)
Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine (1990) (51)
Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine (1995) (50)
Structure-activity relationships of MDMA-like substances. (1989) (49)
Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia (2014) (48)
Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats (2002) (47)
A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor (2002) (47)
Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin (1999) (47)
Ambient Temperature Effects on 3,4-Methylenedioxymethamphetamine-Induced Thermodysregulation and Pharmacokinetics in Male Monkeys (2007) (46)
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. (2006) (46)
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. (1999) (46)
Structure–activity relationships of serotonin 5‐HT2A agonists (2012) (46)
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). (1991) (46)
Social Reactivity and D1 Dopamine Receptors: Studies in Mice Selectively Bred for High and Low Levels of Aggression (1994) (44)
Binding to the serotonin 5-HT2 receptor by the enantiohers of 125I-DOI (1987) (44)
Dopamine agonist properties of N-alkyl-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines. (1981) (43)
5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. (1996) (43)
Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. (2001) (43)
Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. (2013) (41)
Structural correlation between apomorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens. (1976) (41)
5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. (1993) (40)
Differential phospholipase C activation by phenylalkylamine serotonin 5‐HT2A receptor agonists (2005) (40)
“Full” dopamine D1 agonists in human caudate: Biochemical properties and therapeutic implications (1995) (39)
Structure-activity relationships of phenethylamine hallucinogens. (1981) (39)
α1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats (2007) (39)
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. (1994) (38)
An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA (2002) (38)
Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. (1990) (38)
Psilocybin: from ancient magic to modern medicine (2020) (36)
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol (2002) (36)
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. (1994) (36)
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). (2018) (35)
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. (1991) (35)
Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. (1977) (35)
N,N-dimethyltryptamine and the pineal gland: Separating fact from myth (2018) (35)
Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue (1991) (34)
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B (2004) (34)
Is LSD toxic? (2018) (34)
Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). (2017) (33)
Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. (1988) (33)
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI (2009) (33)
Benzofuran bioisosteres of hallucinogenic tryptamines. (1992) (33)
Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists (2005) (32)
Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine. (1995) (32)
5-iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine (1991) (32)
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. (2008) (32)
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration (1989) (31)
Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. (1993) (30)
Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats. (1986) (30)
Potential psychotomimetics. 2. Rigid analogs of 2,5-dimethoxy-4-methylphenylisopropylamine (DOM, STP). (1974) (30)
Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG) (2004) (30)
Novel serotonergic agents. (1993) (30)
Silica subsurface amine effect on the chemical stability and chromatographic properties of end-capped immobilized artificial membrane surfaces. (1991) (30)
The History of Psychedelics in Psychiatry. (2020) (29)
A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. (2006) (29)
D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. (2006) (28)
Stereoselective Synthesis of trans-2-(Indol-3-yl)cyclopropylamines: Rigid Tryptamine Analogs (1995) (28)
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). (2018) (28)
Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. (1994) (27)
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists. (1982) (27)
WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D4 receptor activation (2009) (27)
Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats (1991) (27)
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats (2004) (26)
Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA). (1996) (26)
Synthesis and adrenergic blocking effects of 2-(alkylamino)-3,4-dihydroquinazolines. (1980) (26)
Studies on the mechanism of p-chloroamphetamine neurotoxicity. (1996) (26)
Effects of psychotomimetics on vascular strips: studies of methoxylated amphetamines and optical isomers of 2,5-dimethoxy-4-methylamphetamine and 2,5-dimethoxy-4-bromoamphetamine. (1974) (26)
LSD and phenethylamine hallucinogens: new structural analogy and implications for receptor geometry. (1978) (26)
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. (1985) (25)
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. (1997) (25)
Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines. (1973) (25)
3,3',5'-Tri-O-methylpiceatannol and 4,3',5'-tri-O-methylpiceatannol: improvements over piceatannol in bioactivity. (1987) (24)
Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents (1998) (24)
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. (2003) (24)
'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. (2008) (24)
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. (1995) (24)
Potential psychotomimetics. Bromomethoxyamphetamines. (1971) (24)
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor (2012) (24)
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA). (1998) (23)
The Development of Novel Dopamine Agonists (1983) (23)
Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA). (1975) (23)
Synthesis and SAR exploration of dinapsoline analogues. (2004) (22)
Engineered zinc‐binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter (2006) (22)
Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum (2002) (22)
Studies of the relationship between molecular structure and hallucinogenic activity (1986) (22)
Neurotoxicity of MDMA (ecstasy): beyond metabolism. (2005) (22)
8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. (2004) (22)
Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). (2017) (21)
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. (2006) (21)
Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. (1981) (21)
MDMA transiently alters biogenic amines and metabolites in mouse brain and heart (1989) (20)
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue. (1987) (20)
Formal synthesis of clavicipitic acid based on biosynthetic proposal (1988) (20)
Distinct Recognition of Substrates by the Human and Drosophila Serotonin Transporters (2003) (20)
Comparative Molecular Field Analysis Using Selectivity Fields Reveals Residues in the Third Transmembrane Helix of the Serotonin Transporter Associated with Substrate and Antagonist Recognition (2008) (20)
Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens (2000) (20)
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. (1995) (20)
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. (1998) (19)
Potential psychotomimetics. 2-Amino-1,2,3,4-tetrahydronaphthalene analogs. (1973) (19)
5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat (1997) (19)
Structural variation and (+)-amphetamine-like discriminative stimulus properties (1991) (19)
Complex stimulus properties of LSD: a drug discrimination study with α2-adrenoceptor agonists and antagonists (1995) (19)
Effects of S-(+)- and R-(-)-3,4,dimethoxyphenylisopropylamines in the rat. (1972) (19)
Sulfur analogs of psychotomimetic amines. (1976) (18)
D1 Dopamine Receptors of NS20Y Neuroblastoma Cells Are Functionally Similar to Rat Striatal D1 Receptors (1991) (18)
Ligand-Specific Roles for Transmembrane 5 Serine Residues in the Binding and Efficacy of Dopamine D1 Receptor Catechol Agonists (2012) (18)
Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists. (1987) (18)
Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum (1995) (18)
Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. (1998) (18)
Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane. (1984) (17)
Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (17)
Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogues. (1977) (17)
Comparison of electrospray ionization and atmospheric pressure photoionization liquid chromatography mass spectrometry methods for analysis of ergot alkaloids from endophyte-infected sleepygrass (Achnatherum robustum). (2016) (17)
Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. (2002) (17)
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. (1996) (17)
Striatal dopamine D1 receptor suppression impairs reward-associative learning (2017) (17)
1-Methylpyridinium-4-(4-phenylmethanethiosulfonate) iodide, MTS-MPP+, a novel scanning cysteine accessibility method (SCAM) reagent for monoamine transporter studies. (2007) (16)
1 Medicinal Chemistry and Structure-Activity Relationships (2009) (16)
Molecular Drug Design and Dopamine Receptors (1997) (16)
One-pot Claisen rearrangement/O-methylation/alkene isomerization in the synthesis of ortho-methoxylated phenylisopropylamines (1996) (16)
Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors (2009) (16)
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. (1992) (16)
Synthesis of high specific activity 125I‐ and 123I‐labelled enantiomers of 2,5‐dimethoxy‐4‐iodophenylisopropylamine (DOI) (1988) (16)
A simple procedure for the preparation of indoles (1984) (16)
Robinlin: a novel bioactive homo-monoterpene from Robinia pseudoacacia L. (Fabaceae). (2001) (15)
Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models. (2018) (15)
Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (1991) (15)
Resolution and absolute configuration of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analogue. (1979) (15)
Synthesis and Pharmacological Examination of Benzofuran, Indan, and Tetralin Analogues of 3,4‐(Methylenedioxy)amphetamine. (1994) (15)
Mapping the Catechol Binding Site in Dopamine D1 Receptors: Synthesis and Evaluation of Two Parallel Series of Bicyclic Dopamine Analogues (2011) (15)
Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. (2003) (15)
Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. (1995) (14)
Assessment of the role of α-methylapinine in the neurotoxicity of MDMA (1991) (14)
Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice. (1979) (14)
Nonneurotoxic Tetralin and Indan Analogues of 3,4‐(Methylenedioxy)amphetamine (MDA). (1990) (14)
Serotonin-Related Psychedelic Drugs (2009) (14)
The Heffter Research Institute: Past and Hopeful Future (2014) (14)
Synthesis and evaluation of N,N-di-n-propyltetrahydrobenz[f]indol-7-amine and related congeners as dopaminergic agonists. (1989) (14)
Indan Analogs of Fenfluramine and Norfenfluramine Have Reduced Neurotoxic Potential (1998) (14)
Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP). (1973) (14)
A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene. (1982) (14)
Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues (1989) (13)
Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. (2015) (13)
trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo(a)phenanthridine: A Highly Potent Selective Dopamine D1 Full Agonist. (1990) (13)
Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. (2011) (13)
Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives (1994) (13)
Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. (2002) (13)
A New, Simple Procedure for the Preparation of 8-Methoxy-2-Tetralone (1995) (13)
Effects of para-methoxyamphetamine (PMA) on the cardiovascular system of the dog. (1974) (13)
A reported "new synthesis of lysergic acid" yields only the derailment product: methyl 5-methoxy-4,5-dihydroindolo[4,3-f,g]quinoline-9-carboxylate. (2012) (13)
2,3-Dihydroxy-9-amino-9,10-dihydrophenanthrene, a rigid congener of dopamine and isoapomorphine. (1978) (13)
Structural Analysis of the Extracellular Entrance to the Serotonin Transporter Permeation Pathway* (2010) (12)
Dopamine D1 receptor agonists as antiparkinson drugs. (1998) (12)
Serotonin and serotonin receptors in hallucinogen action (2020) (12)
Stimulation of presynaptic dopamine autoreceptors by 4-(2-di-n-propylaminoethyl) indole (DPAI). (1984) (12)
trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT2 receptor family (2012) (12)
A new view of the structural relationship between LSD and mescaline (1977) (11)
Molecular modeling study of tubulosine and other related ipecac alkaloids (1998) (11)
Effect of beta-alkyl substitution on D-1 dopamine agonist activity: absolute configuration of beta-methyldopamine. (1987) (11)
4‐Aryl‐Substituted 2,5‐Dimethoxyphenethylamines: Synthesis and Serotonin 5‐HT2A Receptor Affinities (2009) (11)
Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: lack of LSD-like biological activity. (1984) (11)
Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors (2010) (11)
Parkinson's disease and D 1 dopamine receptors (2001) (11)
Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane. (1999) (11)
An improved synthesis of 6-hydroxy-4-[2-(di-n-propylamino)ethyl]indole (1990) (10)
Sleeplessness (1885) (10)
EFFECTS OF CERTAIN HALLUCINOGENIC AMPHETAMINE ANALOGS ON THE RELEASE OF (3H)-SEROTONIN FROM RAT BRAIN SYNAPTOSOMES (1982) (10)
Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. (1993) (10)
Cactus alkaloids. XLVII. N alpha-dimethylhistamine, a hypotensive component of Echinocereus triglochidiatus. (1982) (10)
Experimental evaluation of the generalized vibrational theory of G protein-coupled receptor activation (2017) (10)
Distinct Molecular Recognition of Psychostimulants by Human and Drosophila Serotonin Transporters (2004) (10)
CHARACTERIZATION OF THREE NEW PSYCHOTOMIMETICS (2002) (10)
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. (1999) (10)
A 5-HT2C receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference (2011) (9)
Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease (2012) (9)
Potential serotonin 5-HT1A and dopamine D4 receptor modulation of the discriminative stimulus effects of amphetamine in rats (2011) (9)
Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine. (1997) (9)
LSD and Its Lysergamide Cousins (9)
Steric effects of substituents on phenethylamine hallucinogens. 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring. (1979) (9)
A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. (2001) (9)
CACTUS ALKALOIDS. LIII. CORYPHANTHINE AND O-METHYL- CANDICINE, TWO NEW QUATERNARY ALKALOIDS FROM CORYPHANTHA GREENWOODII (1983) (9)
Serotonin Release is Responsible for the Locomotor Hyperactivity in Rats Induced by Derivatives of Amphetamine Related to MDMA (1991) (8)
Conformationally Restricted Tetrahydro-1-benzoxepin Analogues of Hallucinogenic Phenethylamines. (1995) (8)
Alternative Formal Synthesis of the Potent D1 Dopamine Agonist Dihydroxy-2,3,7,11b-tetrahydro-1H- naphth[1,2,3-de]isoquinoline: Dinapsoline (1999) (8)
Dopamine vascular actions of N-substituted derivatives of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN). (1979) (8)
Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors (1991) (8)
A Practical and Cost-Effective Synthesis of 6,7-Dimethoxy-2-tetralone (1999) (8)
Synthesis and Pharmacological Examination of 1‐(3‐Methoxy‐4‐methylphenyl)‐2‐aminopropane and 5‐Methoxy‐6‐methyl‐2‐aminoindan: Similarities to 3,4‐(Methylenedioxy)methamphetamine (MDMA). (1991) (8)
Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients. (1975) (8)
Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. (2010) (8)
Effects of rigid amphetamine analogs on vascular strips: studies of 2-aminotetrahydronaphthalene and 2-aminoindan derivatives. (1974) (8)
Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand. (2012) (8)
Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al. (2006) (8)
A new approach for the synthesis of (±)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine (dihydrexidine) (1996) (8)
Isomeric cyclopropyl ring-methylated homologues of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analogue. (1982) (7)
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. (1995) (7)
Therapeutic and adjunctive applications of an imidazoline anti-inflammatory agent. (1983) (7)
Dinapsoline : Characterization of a D 1 Dopamine Receptor Agonist in a Rat Model of Parkinson ’ s Disease (2001) (7)
A simple organ bath for electrical stimulation and superfusion of rat brain slices. (1986) (7)
Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent (1995) (7)
Mescaline analogs: substitutions at the 4-position. (1978) (7)
Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. (2012) (7)
AN IMPROVED SYNTHESIS OF 1-BENZOYL-4-KETO-1,2,2A,3,4,5-HEXAHYDROBENZ [cd]INDOLE (1977) (7)
Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. (1980) (7)
SYNTHESIS AND LSD-LIKE DISCRIMINATIVE STIMULUS PROPERTIES IN A SERIES OF N(6)-ALKYL NORLYSERGIC ACID N,N-DIETHYLAMIDE DERIVATIVES (1985) (7)
New victims of current drug laws (2013) (7)
Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. (2011) (6)
Unreliability of the rat stomach fundus as a predictor of hallucinogenic activity in substituted phenethylamines. (1984) (6)
Lysergamides revisited. (1994) (6)
Discovery of novel psychoactive drugs: has it ended? (1987) (6)
An Efficient Synthesis of the Potent Dopamine D1 Agonist Dinapsoline by Construction and Selective Reduction of 2′-Azadimethoxybenzanthrone (2001) (6)
AN IMPROVED METHOD FOR THE PREPARATION OF CYCLIC CONJUGATED NITROOLEFINS (1996) (5)
C(2)-Methylation abolishes DA1 dopamine agonist activity of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (6,7-ADTN): steric intolerance by the receptor. (1984) (5)
Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA. (1991) (5)
Mechanisms and Issues Relating to the Use of D1-like Dopamine Receptor Agonists for Age-related Illnesses: Parkinson’s Disease and Memory and Cognition (2004) (5)
Pharmacologic evaluation of 3,4-dimethoxyphenylpropenes and 3,4-dimethoxyphenylpropanediols. (1972) (5)
Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release (2005) (5)
An economical screen for phenethylamine-type hallucinogens: mouse ear scratching. (1979) (5)
Tomoxetine and the stereoselectivity of drug action (1987) (5)
Synthesis and Pharmacological Characterization of a Series of Geometrically Constrained 5-HT 2 A / 2 C Receptor Ligands (5)
The Pharmacodynamic Characterization of an Antisense Oligonucleotide Against Monoamine Oxidase-B (MAO-B) in Rat Brain Striatal Tissue (2001) (4)
Chemistry and pharmacological evaluation of 1-phenyl-2-propanols and 1-phenyl-2-propanones. (1971) (4)
3,4- Methylenedioxy amphetamine (MDA) Analogues (1989) (4)
Borohydride Reduction of Estrone. Demonstration of Diastereoselectivity in the Undergraduate Organic Chemistry Laboratory (2008) (4)
(±)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors (1996) (4)
Homologous Desensitization of the D 1 A Dopamine Receptor : Efficacy in Causing Desensitization Dissociates from Both Receptor Occupancy and Functional Potency 1 (1998) (4)
Nickel Boride/Hydrazine Hydrate: Reduction of Aromatic and Aliphatic Nitro Compounds. Synthesis of 4‐(Benzyloxy)indole and α‐Alkyltryptamines. (1987) (4)
Emerging Designer Drugs (2014) (4)
SUBSTITUENT BRANCHING IN PHENETHYLAMINE‐TYPE HALLUCINOGENS: A COMPARISON OF 1‐(2,5‐DIMETHOXY‐4‐(2‐BUTYL)PHENYL)‐2‐AMINOPROPANE AND 1‐(2,5‐DIMETHOXY‐4‐(2‐METHYLPROPYL)PHENYL)‐2‐AMINOPROPANE (1984) (3)
Preliminary evaluation of 4-(2-N,N-dialkylaminoethyl)indoles as potential dopamine agonists (1991) (3)
Comparison of the enantiomers of ( ± )-doxanthrine , a high efficacy full dopamine D 1 receptor agonist , and a reversal of enantioselectivity at D 1 versus alpha 2 C adrenergic receptors Running Title : Novel enantioselectivity of doxanthrine (2015) (3)
SYNTHESIS AND ADRENERGIC BLOCKING EFFECTS OF 2-(ALKYLAMINO)-3,4-DIHYDROQUINAZOLINES (1981) (3)
A Novel and Efficient Synthesisof Dihydrexidine (2009) (3)
Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated (2022) (3)
Apomorphine-like effect of an aminotetralin on the linguomandibular reflex of the cat. (1975) (3)
Effect of α-methyltryptamine on spontaneous activity in mice (1979) (3)
Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). (1991) (3)
Drugs in Central Nervous System Disorders (1986) (3)
Serotonin Neurotoxicity in Rats After Combined (2001) (3)
Synthesis and serotonin-like activity of 2-amino-5,8-dimethoxy-6-methyl-1,2-dihydronaphthalene. (1981) (3)
Cactus alkaloids XXXIII: beta-phenethylamines from the Guatemalan cactus Pilosocereus maxonii. (1977) (3)
A Facile Method for the Preparation of Pure cis‐2,4‐Pentanediol (2004) (3)
Helix XI contributes to the entrance of the serotonin transporter permeation pathway (2008) (3)
Native fluorescence and hallucinogenic potency of some amphetamines (2005) (2)
Stereoselective Synthesis of trans‐2‐(Indol‐3‐yl)cyclopropylamines: Rigid Tryptamine Analogues. (1995) (2)
Further Definition of the D1 Dopamine Receptor Pharmacophore: Synthesis of trans-6,6a,7,8,9,13b-Hexahydro-5H-benzo(d)naphth(2,1-b) azepines as Rigid Analogues of β-Phenyldopamine. (1997) (2)
Effect of alpha-methyltryptamine on spontaneous activity in mice. (1979) (2)
The use of rigid analogues to probe hallucinogen receptors. (1978) (2)
1‐Methyl‐3‐piperidone and 1‐methyl‐3‐pyrrolidone derivatives from a dieckmann reaction (1973) (2)
A new potent and selective DA1 (vascular) dopamine receptor agonist (1990) (2)
A New, Simple Procedure for the Preparation of 8‐Methoxy‐2‐tetralone. (1995) (1)
Formal Synthesis of Clavicipitic Acid Based on a Biosynthetic Proposal. (1989) (1)
An Efficient Synthesis of the Potent Dopamine D1 Agonist Dinapsoline (IX) by Construction and Selective Reduction of 2′-Azadimethoxybenzanthrone. (2001) (1)
The consequences of receptor reserve on agonist-directed trafficking at the serotonin2A receptor (2001) (1)
LIPOPHILICITY AND SEROTONIN AGONIST ACTIVITY IN A SERIES OF 4-SUBSTITUTED MESCALINE ANALOGS (1977) (1)
Author’s reply (2018) (1)
A Chemogenetic Platform for Spatio-temporal Control of β-arrestin Translocation and Signaling at G protein-Coupled Receptors (2018) (1)
Crystal structure of the LSD-bound 5-HT2B receptor (2017) (1)
Stereoselective effects of MDMA on inhibition of monoamine uptake (1986) (1)
Highly Selective Neurotoxins. Basic and Clinical Applications Edited by R. M. Kostrzewa. Humana Press, Towota, NJ. 1998. xii + 404 pp. 16 × 23.5 cm. ISBN 0-89603-465-8. $125.00. (1998) (1)
Addressing the need for rigor in the rebirth of hallucinogen research (2017) (1)
Designer Drugs Directory By Karel Valter and Philippe Arrizabalaga. Edited by Jean-Claude Landry. Elsevier Science, Lausanne, Switzerland. 1998. 212 pp. 17 x 25 cm. ISBN 0-444-20525-X. $154.00. (1999) (1)
Synthesis und Evaluation of 2,3-Dihydrobenzofuran Analogues of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane: Drug Discrimination Studies in Rats. (1986) (1)
The Medicinal Chemistry of Phenethylamine Psychedelics (1)
ISOMERIC CYCLOPROPYL RING-METHYLATED HOMOLOGS OF TRANS-2-(2,5-DIMETHOXY-4-METHYLPHENYL)CYCLOPROPYLAMINE, AN HALLUCINOGEN ANALOG (1982) (1)
One‐Pot Claisen Rearrangement/O‐Methylation/Alkene Isomerization in the Synthesis of ortho‐Methoxylated Phenylisopropylamines. (1997) (1)
In vitro and in vivo evaluation of cis-methyl-phencyclidine (CIS-MPCP) as a potential antagonist of phencyclidine (PCP). (1983) (1)
An unusual formation of a novel spiroisoquinolone ring (1995) (1)
SYNTHESIS OF 2-(ALKYLAMINO)-5,6- AND -6,7-DIHYDROXY-3,4-DIHYDROQUINAZOLINES AND EVALUATION AS POTENTIAL DOPAMINE AGONISTS (1982) (1)
Excitatory Amino Acids and Their Antagonists (2015) (1)
A NEW, POTENT, CONFORMATIONALLY-RESTRICTED ANALOG OF AMPHETAMINE: 2-AMINO-1,2-DIHYDRONAPHTHALENE (1982) (1)
A Novel and Efficient Synthesis of Dihydrexidine A New Synthesis of Dihydrexidine (2009) (1)
Effects of steric interactions on models of charge-transfer complexes: A preliminary report (2009) (1)
Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (0)
EJP 53172 5H T 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits (2002) (0)
1-( 2 , 5-Dimethoxy-4-( trifluoromethy 1 ) phenyl )-2-aminopropane : A Potent Serotonin ~-H T ~ A / ~ c Agonist (2001) (0)
Striatal dopamine D 1 receptor suppression impairs reward-associative learning Running title : Striatal D 1 receptors in reward learning (2017) (0)
SYNTHESIS AND SEROTONIN-LIKE ACTIVITY OF 2-AMINO-5,8-DIMETHOXY-6-METHYL-1,2-DIHYDRONAPHTHALENE (1981) (0)
An Unusual Formation of a Novel Spiroisoquinolone Ring. (1995) (0)
Comparison of the behavioral effects of para-chloroamphetamine, chlordimeform, quipazine, and intraventricular serotonin in the rat. (1978) (0)
RESOLUTION AND ABSOLUTE CONFIGURATION OF TRANS-2-(2,5-DIMETHOXY-4-METHYLPHENYL)CYCLOPROPYLAMINE, A POTENT HALLUCINOGEN ANALOG (1979) (0)
Hypothetical Models Of Dopamine D-1 Receptor (1990) (0)
Allylbenzene analogs of Δ9-tetrahydrocannabinol as tumor growth inhibitors (1977) (0)
SA113. Dopamine D1 Receptor Activation Improves Reward-Associative Learning in a Mouse Probabilistic Learning Task (2017) (0)
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor (2012) (0)
8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph(1,2,3-de)isoquinoline: A Potent Full Dopamine D1 Agonist Containing a Rigid β- Phenyldopamine Pharmacophore. (1996) (0)
2365 – A COMPARATIVE STUDY OF N-N-DISUBSTITUTED ANALOGS OF DOPAMINE AND 2-AMINO-6,7-DIHYDR0XY-TETRALIN (1978) (0)
Behavioral techniques in neuroreceptor research. (1983) (0)
CONFORMATIONAL ENERGY DIFFERENCES BETWEEN SIDE CHAIN ALKYLATED ANALOGS OF THE HALLUCINOGEN 1-(2,5-DIMETHOXY-4-METHYLPHENYL)-2-AMINOPROPANE (1980) (0)
Allylbenzene analogs of delta9-tetrahydrocannabinol as tumor growth inhibitors. (1977) (0)
The Chemistry of Mind-Altering Drugs. History, Pharmacology, and Cultural Context By Daniel M. Perrine. American Chemical Society, Washington, D.C. 1996. x + 480 pp. 17.5 × 25 cm. ISBN 0-8412-3253-9. $39.95. (1997) (0)
STRUCTURE-ACTIVITY RELATIONSHIPS OF PHENETHYLAMINE HALLUCINOGENS (1982) (0)
2,3-DIHYDROXY-9-AMINO-9,10-DIHYDROPHENANTHRENE, A RIGID CONGENER OF DOPAMINE AND ISOAPOMORPHINE (1978) (0)
C-ring expanded analogs of doxanthrine:conformation plays a critical role (2011) (0)
An Improved Synthesis of 6-Hydroxy-4-(2-(di-n-propylamino)ethyl)indole. (1990) (0)
Synthesis and Pharmacological Examination of 1-( 3-Methoxy-l-methylphenyl )-2-aminopropane and 5-Methoxy-6-methyl-2-aminoindan : Similarities to 3 , 4-( Met hy 1 enedioxy ) met hamphetamine ( MDMA ) (0)
Hallucinogens. (1964) (0)
(trifluoromethy1)phenyl) -2-aminopropane: A Potent Serotonin ~-HT~A/~c Agonist (1994) (0)
An Improved Method for the Preparation of Cyclic Conjugated Nitroolefins. (1996) (0)
Alternative Formal Synthesis of the Potent D1 Dopamine Agonist Dihydroxy‐2,3,7,11b‐tetrahydro‐1H‐naphth[1,2,3‐de]isoquinoline: Dinapsoline. (1999) (0)
Potential Psychotomimetics . 2 . l Rigid Analogs of 2 , 5-Dimet hoxy-4-met hy lpheny 1 isoDropy lamine ( D OM , STP ) (2001) (0)
C(2)-METHYLATION ABOLISHES DA1 DOPAMINE AGONIST ACTIVITY OF 2-AMINO-6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE (6,7-ADTN): STERIC INTOLERANCE BY THE RECEPTOR (1985) (0)
Reduction of aspirin-induced ulcers by a new imidazoline anti-inflammatory agent (1981) (0)
Translocation of the 5‐Alkoxy Substituent of 2,5‐Dialkoxyarylalkylamines to the 6‐Position: Effects on 5‐HT2A/2C Receptor Affinity. (2002) (0)
Methoxyphenethylamine-ergoline hybrids Novel muscarinic ligands (1995) (0)
Synthesis and Pharmacological Examination of Benzofuran , Indan , and Tetralin Analogues of 3 , 4-( Methy 1 enedioxy ) amphetamine (2002) (0)
DOPAMINE AGONIST PROPERTIES OF N-ALKYL-4-(3,4-DIHYDROXYPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINES (1982) (0)
Synthesis and Evaluation of N,N‐Di(n‐propyl)tetrahydrobenz(f)indol‐7‐amine and Related Congeners as Dopaminergic Agonists. (1990) (0)
A Practical and Cost‐Effective Synthesis of 6,7‐Dimethoxy‐2‐tetralone. (2000) (0)
Signaling snapshots of 5-HT 2B serotonin receptor activated by the prototypical psychedelic LSD (2022) (0)
New fused isoquinolines as receptor ligands dopamine. (1996) (0)
Conformational energy calculations of some amphetamine analogs using a new solvation model (2009) (0)
Synthesis of high specific activity radiohalogenated amphetamine analogues for studies of the serotonin 5‐HT2 receptor (1989) (0)
A Facile Method for the Preparation of Pure cis‐2,4‐Pentanediol. (2004) (0)
Dihydrobenzofuran Analogues of Hallucinogens. Part 4. Mescaline Derivatives. (1998) (0)
Erratum: Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase (Journal of Pharcology and Experimental Therapeutics (2002) 301 (1166-1179)) (2002) (0)
Po ten tial Psychotomimetics . 2-Amino-1 , 2 , 3 , 4-te trahy dro naph thalene Analogs ? (2002) (0)
Stereochemical and NMR Reassignment of 6-Norlysergic Acid Diethylamide and 6-Nor-6-allyllysergic Acid Diethylamide. (1996) (0)
STERIC EFFECTS OF SUBSTITUENTS ON PHENETHYLAMINE HALLUCINOGENS. 3,4-(METHYLENEDIOXY)AMPHETAMINE ANALOGS ALKYLATED ON THE DIOXOLE RING (1980) (0)
SYNTHESIS AND EVALUATION OF SUBSTITUTED 2-PHENYLCYCLOBUTYLAMINES AS ANALOGS OF HALLUCINOGENIC PHENETHYLAMINES: LACK OF LSD-LIKE BIOLOGICAL ACTIVITY (1985) (0)
COMPARISON OF SOLUTION CONFORMATIONAL PREFERENCES FOR THE HALLUCINOGENS BUFOTENIN AND PSILOCIN USING 360-MHZ PROTON NMR SPECTROSCOPY (1981) (0)
Indan Analogues of 3 , 4-( Met hy 1 enedioxy ) amphetamine (2001) (0)
Psychedelic Drugs (2021) (0)
ASYMMETRIC SYNTHESIS OF PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES (1973) (0)
icrodialysis studies on 3 , 4 methylenedioxyamphetamine a related analogues (2002) (0)
Synthesis of Essential Drugs By Ruben Vardanyan and Victor Hruby. Elsevier, Amsterdam, The Netherlands. 2006. xvi + 617 pp. 17 × 24.5 cm. ISBN 10 0-444-52166-6. $240.00. (2006) (0)
POTENTIAL PSYCHOTOMIMETICS PART 2, RIGID ANALOGS OF 2,5-DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM,STP) (1974) (0)
Preliminary Evaluation of 4-(2-N,N-Dialkylaminoethyl)indoles as Potential Dopamine Agonists. (1991) (0)
A New Approach for the Synthesis of (.+-.)-trans-10,11-Dihydroxy-5,6, 6a,7,8,12b-hexahydrobenzo(a)phenanthridine (Dihydrexidine). (1996) (0)
STRUCTURE-ACTIVITY RELATIONSHIPS OF N-SUBSTITUTED DOPAMINE AND 2-AMINO-6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE ANALOGS: BEHAVIORAL EFFECTS IN LESIONED AND RESERPINIZED MICE (1980) (0)
POTENTIAL PSYCHOTOMIMETICS, 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE ANALOGS (1973) (0)
1-METHYL-3-PIPERIDONE AND 1-METHYL-3-PYRROLIDONE DERIVATIVES FROM A DIECKMANN REACTION (1973) (0)
Asymmetric Synthesis of Psycho tomimetic Phenylisopropylamines ' (2009) (0)
SULFUR ANALOGS OF PSYCHOTOMIMETIC AMINES (1977) (0)
Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease (2012) (0)
Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (0)
AN IMPROVED SYNTHESIS OF 1-BENZOYL-4-OXO-1,2,2A,3,4,5-HEXAHYDROBENZ(CD)INDOLE (1978) (0)
Phe340 with super-potent N-benzyl phenethylamine agonists (2006) (0)
Synthesis and Biological Evaluation of a Series of Substituted Benzo(a) phenanthridines as Agonists at D1 and D2 Dopamine Receptors. (1995) (0)
Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (0)
Specific Dopamine D-1 and DA1 Properties of 4-(Mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and Its Tetrahydrothieno(2,3-c)pyridine Analogue. (1988) (0)

This paper list is powered by the following services:

Other Resources About David E. Nichols

en.wikipedia.org

What Schools Are Affiliated With David E. Nichols?

David E. Nichols is affiliated with the following schools:

David E. Nichols's AcademicInfluence.com Rankings